Background
==========

*Candida* species are the main cause of invasive fungal disease, affecting a wide variety of patient populations, including critically ill patients, patients with hematological malignancies, elderly hospitalized patients, solid-organ transplant recipients, and adult diabetic patients \[[@B1]\]. *C. albicans* remains the most common pathogen causing candidemia and invasive candidiasis (C/IC), both worldwide \[[@B1],[@B2]\] and in Asia \[[@B3]\], but other species are becoming increasingly common \[[@B1],[@B4]-[@B7]\]. Moreover, species distribution and susceptibility to antifungal agents, show considerable geographic variation \[[@B3]\]. Therefore, knowledge of local epidemiology is important for the effective management of candidemia.

Crude mortality rates associated with C/IC are substantial, ranging from 30% to 81% according to recent reports \[[@B2],[@B4]\]. Mortality varies according to patient age, pre-existing comorbidities, and the causative *Candida* species; the highest mortality rates are observed with *C. krusei,* followed by *C. tropicalis* and *C. glabrata*\[[@B2],[@B8]\].

Regional data for C/IC in Asia are scarce. A retrospective review of admissions to a Korean intensive care unit reported an incidence of candidemia of 9.1 cases per 1000 admissions, with a notably high crude mortality of 96%, due to a high proportion of patients with malignancy \[[@B9]\]. Four centers in Taiwan reported crude mortality ranging from 43.1% to 60.7% \[[@B10]\], and a tertiary care center in North India reported a decrease in mortality rate from 72.2% to 47% over a 5-year period as awareness of disease prevalence increased \[[@B11]\].

Fluconazole is the most commonly used candidemia therapy, but susceptibility to fluconazole varies, both by *Candida* species and by geographical region \[[@B3]\]. Thus, other antifungal agents are also required that are more effective than fluconazole against *Candida*, particularly in regional populations where *C. albicans* is no longer the most common species causing infection.

The echinocandin anidulafungin is an effective alternative to fluconazole, demonstrating superiority to fluconazole for the treatment of C/IC in a pivotal clinical trial by Reboli *et al.*\[[@B12]\]. However, clinical studies of anidulafungin have so far been conducted mostly in North America and Europe, with few Asian patients studied \[[@B12]-[@B14]\]. Racial groups may differ in terms of epidemiology, disease presentation, drug tolerability, and response to treatment \[[@B8],[@B15]-[@B19]\]. Thus, assessment of potential clinically relevant differences between Asian and Western populations treated with anidulafungin is required. Moreover, the extended-spectrum triazole voriconazole has been reported to have greater *in vitro* activity against most *Candida* species compared with fluconazole \[[@B3]\].

This study aimed primarily to evaluate the efficacy and safety of intravenous (i.v.) anidulafungin for the treatment of documented candidemia in a broad and diverse population of Asian patients, with Acute Physiology and Chronic Health Evaluation (APACHE II) scores ≤ 20. The activity of anidulafungin was investigated across a range of pre-defined patient subgroups. In addition, the relationship between response to treatment and β-D glucan levels was investigated. Step-down therapy to oral voriconazole following at least 5 days of i.v. anidulafungin was permitted, to investigate whether treatment success rates comparable with fluconazole could be achieved \[[@B3]\], whilst providing flexible treatment options, such as reducing the length of i.v. therapy.

Methods
=======

Study design
------------

This was a prospective Phase III, 12-week, open-label, multicenter, non-comparative study (January 2008 to March 2009). The trial was performed in accordance with the Declaration of Helsinki and International Conference on Harmonisation Good Clinical Practice guidelines; each center was also approved by the local institutional review board (IRB) (please see Additional file [1](#S1){ref-type="supplementary-material"} for full details of the IRBs). Periodic monitoring visits were performed by the study sponsor or approved agents. Full ethical approval was obtained at each participating center, and all patients provided written informed consent prior to screening. Patients could withdraw from the trial at any time. The trial was registered on <http://www.clinicaltrials.gov> under the identifier NCT00537329.

Patients
--------

Patients were eligible for participation if they had at least one blood culture positive for *Candida* species (within 96 h of starting study treatment), and clinical evidence of infection within 48 h prior to study enrollment. They were required to be at least 18 years of age, of Asian race, and to have an APACHE II score of ≤ 20. Patients were excluded in the event of: suspected *Candida* osteomyelitis, endocarditis, meningitis, endophthalmitis, septic thrombophlebitis, or hepatosplenic candidiasis; administration of \> 48 h of systemic antifungal therapy within 2 weeks before enrollment; previous history of anidulafungin treatment; hypersensitivity to any echinocandins or azole therapy; an estimated life expectancy of \< 72 h; and pregnancy.

ITT population
--------------

The intent-to-treat (ITT) population comprised all patients who received at least one dose of anidulafungin, and was used for the safety analysis.

MITT population
---------------

The modified ITT (MITT) population comprised all ITT patients with a confirmed diagnosis of candidemia and was used for the efficacy analysis.

Per-protocol population
-----------------------

The per-protocol population comprised MITT patients who were compliant with the study protocol, i.e. patients who received at least 5 days of i.v. anidulafungin (unless deemed a treatment failure after three doses of study medication); had an overall study drug compliance (as measured by pill count) of ≥ 75% and ≤ 120% for oral voriconazole; and did not receive any concomitant systemic antifungal agents.

Study treatment
---------------

Patients received 200 mg i.v. anidulafungin as a single loading dose on Day 1, followed by 100 mg i.v. anidulafungin once daily thereafter for a minimum of 5 days. After 5 days, patients were allowed to step down to 200 mg twice-daily (BID) oral voriconazole (or 100 mg BID if body weight was \< 40 kg). Criteria for step-down therapy were as follows: negative blood culture for *Candida* species; resolution or significant improvement of clinical signs/symptoms of acute invasive fungal disease, and no clinical evidence of invasive fungal disease, as assessed by the investigator; absence of neutropenia (i.e. absolute neutrophil count ≤ 500/mm^3^); hemodynamically stable; patient was able to take oral medication and had a functional gastrointestinal tract; and did not have any contraindications (including contraindicated concomitant medications) to voriconazole. If these conditions were not fulfilled, the patient was continued on anidulafungin until alternative systemic antifungal therapy was required. Treatment with either anidulafungin only or anidulafungin followed by voriconazole was continued as deemed appropriate by the investigator, up to a maximum of 42 days.

Concomitant systemic antifungal agents were not permitted during the study, although topical antifungal agents were allowed at the investigators' discretion. All other treatments (including antimicrobial and antiviral agents) indicated for the primary illness and supportive medications were continued throughout the study.

Laboratory monitoring
---------------------

Blood cultures were taken on Days 1--6, or until a negative culture for *Candida* species was obtained. If the blood culture remained positive on Day 6, a repeat blood culture was carried out on Day 7 and then weekly thereafter, until a negative result was reported. The presence of *Candida* species was initially determined at local laboratories. Blood samples for the Fungitell β-D glucan assay (Associates of Cape Cod, East Falmouth, MA, USA) were analyzed by a single reference laboratory for the study \[[@B20]\]. Batch samples, prepared by the local laboratory, were sent to a central laboratory in each participating country for confirmation of pathogen identification and susceptibility testing to anidulafungin and voriconazole. Isolates with an anidulafungin minimum inhibitory concentration (MIC) of ≤ 2 μg/ml were considered susceptible, while those with an MIC of \> 2 μg/ml were considered non-susceptible based on Pfaller *et al.*\[[@B21]\]. Voriconazole breakpoints used were ≤ 1 μg/ml (susceptible), \> 1 to 4 μg/ml (susceptible dose-dependent), and \> 4 μg/ml (resistant) based on Pfaller *et al.*\[[@B22]\].

Efficacy endpoints
------------------

The primary endpoint of the study was the proportion of patients in the MITT population with successful global response at end of all treatment (EOT) on or before Day 42. Global response was deemed successful if there was both clinical success (defined as cure -- resolution of signs and symptoms of candidemia, or significant improvement -- incomplete but significant resolution of signs and symptoms of candidemia) and microbiological success (defined as eradication if follow-up culture result is negative for *Candida* species, or presumed eradication if follow-up blood cultures were not available, but the clinical outcome was defined as success). Failure of response was defined as no significant improvement in signs and symptoms, death due to candidemia, or positive follow-up blood culture result. Indeterminate response included death not attributable to candidemia, or patient lost to follow-up. Missing values for patients who withdrew prematurely from the study with a documented failure were imputed using the last observation carried forward (LOCF) approach. To ensure consistency across studies of similar design conducted globally, a decision was made post hoc to include missing and indeterminate values as failures.

Secondary efficacy endpoints included: global response rate and clinical and microbiological responses at the end of i.v. anidulafungin treatment (EOIT), at 2 and 6 weeks follow-up visits after EOT and at the end of 12 weeks from baseline; time to death, mortality attributed to candidemia and all-cause mortality. Global response rates at EOT were assessed in pre-defined patient subgroups and in patients with risk factors for candidemia. Pre-defined subgroups included neutropenic status and *Candida* species isolated at baseline. Risk factors for candidemia included central venous catheter, renal insufficiency, post-surgery status, age ≥ 65 years, chemotherapy within the previous 3 months, and solid organ transplantation.

Safety assessments
------------------

The safety and tolerability analyses of anidulafungin were conducted throughout the study on the ITT population. Safety assessments were measured using adverse-event (AE) monitoring, clinical laboratory parameters, fundoscopy, physical and neurological examination, and vital-sign measurements.

All AEs and serious AEs were reported to the investigator and noted in the case report form, using the Medical Dictionary for Regulatory Activities coding system (Version 12.0). The investigator was required to assess the causality and severity of the AE.

Statistical analysis
--------------------

It was planned to enroll 100 patients for this study, assuming an overall response rate of 75%, the 95% confidence interval (CI) for the percentage of patients responding to treatment would range from 66.3% to 83.7%, allowing for 5% non-evaluability based on the Reboli *et al.* study \[[@B12]\].

For the global, clinical, and microbiologic success rates in the MITT population, a two-sided exact (Clopper-Pearson) 95% CI was calculated \[[@B23]\]. In addition, descriptive summaries were provided for all secondary efficacy endpoints. Continuous outcomes were summarized by the number of observations, mean, standard deviation (SD), median, and range. Categorical outcomes were summarized as count and percentage in each category.

Results
=======

Study population
----------------

Participants were recruited from 13 study centers across Asia. Due to difficult enrollment, the study was closed before target enrollment could be met. Forty-three patients were studied; however, one patient did not have a confirmed documented diagnosis of candidemia and therefore only 42 patients were included in the MITT population. Eighteen patients were \> 65 years, the largest age subgroup. Twenty-one patients had a central venous catheter up to 1 month before baseline (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). At the start of the study, 11 patients had hepatobiliary disorders, 15 had renal and urinary disorders, and 7 patients were receiving chemotherapy.
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###### 

Patient baseline characteristics

  **Baseline characteristic**    **(n = 43)**
  ----------------------------- ---------------
  Age, years                            
    18--44                            10
    45--64                            15
    ≥ 65                              18
    Mean ± SD                    56.5 (± 18.5)
    Range                           19--91
  Gender, % of patients                 
    Male                             53.5
    Female                           46.5
  Race, n (%)                           
    Asian                          43 (100)
  Weight^a^, kg                         
    Mean ± SD                    57.5 (± 12.2)
    Range                         32.0--84.0
  Height^b^, cm                         
    Mean ± SD                    162.4 (± 7.4)
    Range                        148.0--180.0
  Baseline pathogen^c^, n (%)           
    *Candida tropicalis*           18 (41.9)
    *C. albicans*                  14 (32.6)
    *C. glabrata*                  6 (14.0)
    *C. parapsilosis*               4 (9.3)
    *C. rugosa*                     1 (2.3)
    No pathogen isolated            1 (2.3)

^a^Data available from 41 patients.

^b^Data available from 38 patients.

^c^Patients could have more than one pathogen isolated at baseline.

Abbreviation used: *SD*, standard deviation.

The most common *Candida* species isolated was *C. tropicalis* (41.9%, 18/43 patients), followed by *C. albicans* (32.6%, 14/43 patients). Forty-one of the 43 isolates were tested for susceptibility to study treatment. Susceptibility to anidulafungin was 97.6% (40/41) for all *Candida* isolates; one *C. parapsilosis* isolate had an MIC value of \> 4 μg/ml. Susceptibility to voriconazole was 90.2% (37/41). For *C. albicans*, two isolates had MIC values \> 4 μg/ml, and one isolate had an MIC value between \> 1 and 4 μg/ml. For *C. tropicalis*, one isolate had an MIC \> 4 μg/ml and another isolate had an MIC value between \> 1 and 4 μg/ml.

Treatment duration
------------------

Duration and dose by route of treatment is presented in Table [2](#T2){ref-type="table"}. The median duration of i.v. anidulafungin was 10.0 days (range, 1.0 to 37.0 days). Fourteen patients stepped down to oral voriconazole therapy, with an overall median duration of 10 days (range, 4.0 to 38.0 days).

###### 

Duration and dose by route of treatment; ITT population

  **Parameter**         **(n = 43)**    
  ------------------- ----------------- -----------------
  Duration, days^a^                              
    n                        43                14
    Mean ± SD           11.0 (± 6.81)     12.6 (± 8.89)
    Median                  10.0              10.0
    Range                 1.0--37.0         4.0--38.0
  Dose, mg/day                                   
    n                        43                14
    Mean ± SD          117.8 (± 24.09)   364.8 (± 72.86)
    Median                  110.0             400.0
    Range               102.7--200.0      193.8--400.0

^a^Includes only days on which any dose was taken.

Abbreviations used: *ITT*, intent-to-treat; *SD*, standard deviation.

Efficacy
--------

The global response rate (clinical + microbiological response) at EOT in the MITT population was 73.8% (95% CI, 58.0--86.1 \[31/42 patients\]) for the primary endpoint, increasing to 79.4% (95% CI, 62.1--91.3 \[27/34 patients\]) in the per-protocol group (Table [3](#T3){ref-type="table"}). Failure occurred in 11.9% of patients (5/42 patients) (Table [3](#T3){ref-type="table"}). Secondary endpoints included global response at EOIT, which was 78.6% (33/42 patients) (Table [4](#T4){ref-type="table"}).

###### 

Clinical, microbiological, and global responses at the end of all treatment

  **Parameter**                                  **MITT population**            **PP population**
  ----------------------------------------- ----------------------------- -----------------------------
  **Clinical response, % \[n/N\]**                                        
  Success (95% CI)                           76.2 (60.5--87.9) \[32/42\]   82.4 (65.5--93.2) \[28/34\]
  Cure                                             64.3 \[27/42\]                67.6 \[23/34\]
  Improvement                                       11.9 \[5/42\]                 14.7 \[5/34\]
  Failure^a^                                        4.8 \[2/42\]                  5.9 \[2/34\]
  Indeterminate                                     14.3 \[6/42\]                 5.9 \[2/34\]
  Not assessed                                      4.8 \[2/42\]                  5.9 \[2/34\]
  **Microbiological response, % \[n/N\]**                                 
  Success (95% CI)                           81.0 (65.9--91.4) \[34/42\]   82.4 (65.5--93.2) \[28/34\]
  Eradication                                      73.8 \[31/42\]                73.5 \[25/34\]
  Presumed eradication                              7.1 \[3/42\]                  8.8 \[3/34\]
  Failure                                           2.4 \[1/42\]                  2.9 \[1/34\]
  Not assessed                                      16.7 \[7/42\]                 14.7 \[5/34\]
  **Global response, % \[n/N\]**                                          
  Success (95% CI)                           73.8 (58.0--86.1) \[31/42\]   79.4 (62.1--91.3) \[27/34\]
  Failure                                           11.9 \[5/42\]                 8.8 \[3/34\]
  Not assessed                                      14.3 \[6/42\]                 11.8 \[4/34\]

Abbreviations used: *CI*, confidence interval; *MITT*, modified intent-to-treat; *PP*, per protocol.

###### 

Clinical, microbiological, and global response rates at various pre-defined efficacy timepoints throughout the study in the MITT population

                                  **MITT population**                   
  ------------------------------ --------------------- ---------------- ----------------
  End of intravenous treatment      81.0 \[34/42\]      85.7 \[36/42\]   78.6 \[33/42\]
  (65.9--91.4)                       (71.5--94.6)        (63.2--89.7)   
  2 weeks after EOT                 83.9 \[26/31\]      80.6 \[25/31\]   75.0 \[24/32\]
  (66.3--94.5)                       (62.5--92.5)        (56.6--88.5)   
  6 weeks after EOT                 56.7 \[17/30\]      56.7 \[17/30\]   54.8 \[17/31\]
  (37.4--74.5)                       (37.4--74.5)        (36.0--72.7)   
  12 weeks after baseline           54.8 \[17/31\]      51.6 \[16/31\]   50.0 \[16/32\]
  (36.0--72.7)                       (33.1--69.8)        (31.9--68.1)   

Abbreviations used: *CI*, confidence interval; *EOT*, end of all treatment; *MITT*, modified intent-to-treat.

Clinical and microbiological responses for the MITT analysis set were also summarized by baseline infection pathogen susceptibility (data not shown). Clinical response rates were slightly lower overall than microbiological response rates. Clinical success was documented in 76.2% of patients, with microbiological success in 81%. Only two patients (4.8%) experienced clinical failure, with one patient (2.4%) having documented pathogen persistence. Clinical assessment was indeterminate for six patients (14.3%) (Table [3](#T3){ref-type="table"}). Success rates for the MITT group were 72.2% for *C. tropicalis*, the most common pathogen identified in this study, and 71.4% for *C. albicans* infection. Global success was achieved in 84.6% of patients with previous surgery (11/13 patients), and 58.8% of patients who were over 65 years old. In patients with a central venous catheter, the successful global response was 81.0% (17/21 patients) (Table [5](#T5){ref-type="table"}).

###### 

Global response rates in all predefined patients subgroups among MITT patients

  **Subgroup**                           **Anidulafungin**              
  ------------------------------------- ------------------- ----------- ----------------
  Neutropenic status^a^                                                 
    ANC ≤ 500/mm^3^                            50.0           \[1/2\]      1.3--98.7
    ANC \> 500/mm^3^                           75.7          \[28/37\]     58.8--88.2
  Baseline pathogens^b^                                                 
    *Candida albicans*                         71.4          \[10/14\]     41.9--91.6
    *C. glabrata*                              66.7           \[4/6\]      22.3--95.7
    *C. parapsilosis*                          100.0          \[4/4\]     39.8--100.0
    *C. rugosa*                                100.0          \[1/1\]      2.5--100.0
    *C. tropicalis*                            72.2          \[13/18\]     46.5--90.3
  Previous surgery^c^                                                   
    Any surgery                                84.6          \[11/13\]     54.6--98.1
    Abdominal surgery                          87.5           \[7/8\]      47.3--99.7
  Organ transplantation                                                 
    Kidney, liver, or heart                     0.0           \[0/0\]    Not applicable
  Elderly status                                                        
    Age ≥ 65 years                             58.8          \[10/17\]     32.9--81.6
  Renal insufficiency                                                   
    Creatinine clearance \< 30 ml/min          54.5          \[6/11\]      23.4--83.3
  Use of central venous catheter^c^                                     
    Yes                                        81.0          \[17/21\]     58.1--94.6
  Receiving chemotherapy^d^                                             
    Yes                                        71.4           \[5/7\]      29.0--96.3

^a^ Patients with a missing ANC were not included.

^b^ A patient could have had more than one baseline pathogen.

^c^ Up to 1 month before the baseline visit.

^d^ Up to 3 months before the baseline visit.

Abbreviations used: *ANC*, absolute neutrophil count; *CI*, confidence interval; *MITT*, modified intent-to-treat.

In the MITT population, microbiological success was 80.0% (32/40) in patients with anidulafungin-susceptible isolates and 81.1% (30/37) of those with voriconazole-susceptible isolates; the respective proportions for clinical success were 75.0% (30/40) and 75.7% (28/37). All patients who had isolates resistant to either study agent achieved both clinical and microbiological success. Clinical and microbiological success was reported in all four infections caused by *C. parapsilosis*.

There were no isolates that demonstrated an increase in MICs during the course of the study, including those from patients who were clinical failures where follow-up data were available.

Patients with a successful clinical response had baseline mean β-D-glucan (± SD) levels of 1095.8 ± 968.52 pg/ml, compared to 1447.9 ± 2178.27 pg/ml for patients who suffered clinical failure. At EOT, β-D-glucan levels were 1018.9 ± 783.76 pg/ml in patients who experienced clinical success, and 2917.7 ± 4737.50 pg/ml in patients with clinical failure.

Safety and tolerability profile
-------------------------------

Twelve treatment-related AEs were reported in 10 patients (Table [6](#T6){ref-type="table"}). These included diarrhea and rash, both reported in two patients, and the remaining eight treatment-related AEs were each reported in a single patient (chest discomfort, thirst, drug hypersensitivity, recurrence of candidemia, hypokalemia, confusion, insomnia, and choking). All treatment-related AEs were reported as mild-to-moderate in severity.

###### 

Treatment-emergent adverse events

                                                                                    **Anidulafungin n = 43**  
  -------------------------------------------------------------------------------- -------------------------- ----
  Number of adverse events                                                                    150              12
  Subjects with adverse events                                                                 35              9
  Subjects with serious adverse events                                                         16              1
  Subjects with severe adverse events                                                          13              0
  Subjects discontinued due to adverse events                                                  3               3
  Subjects with dose reduced or temporary discontinuations due to adverse events               2               1
  Deaths, n (%)                                                                                               
    All causality                                                                          10 (23.3)          

The single treatment-related serious AE reported was a recurrence of candidemia (as reported above) in a 54-year-old woman on Day 23, judged by the investigator to be related to voriconazole treatment (after 14 days of voriconazole treatment), which subsequently led to discontinuation of therapy. This patient had *C. glabrata* isolated at baseline, which was susceptible to both voriconazole and anidulafungin (MIC value 0.5 μg/ml for both study drugs). Two other patients also permanently discontinued the study due to AEs (drug hypersensitivity \[n = 1\] and skin rash \[n = 1\]), both considered by the investigator to be related to anidulafungin treatment.

There were 10 deaths (23%) during the study, none considered by the investigator to be related to candidemia or to treatment with study drug. In addition, four patients died after completion of treatment, none considered by the investigator to be related to study treatment.

Discussion
==========

In this study, a regimen of i.v. anidulafungin was assessed for the treatment of documented candidemia in adult Asian patients. The study also included the option to step-down therapy to oral voriconazole. Due to difficult and slow enrollment, the overall sample size was small. However, the efficacy and safety profile of anidulafungin was in line with that previously observed in Western populations.

Efficacy results were generally consistent with those of other studies, including the pivotal trial by Reboli *et al.* that demonstrated better responses with anidulafungin than fluconazole for the treatment of C/IC \[[@B12]\], and an open-label study of anidulafungin dosed at 50 mg, 75 mg, and 100 mg, which reported global success rates (both clinical and microbiological success, i.e. cure/significant improvement of C/IC signs/symptoms and eradication/presumed eradication of *Candida* spp.) of 84%, 90%, and 89%, respectively at EOT, and 72%, 85%, and 83%, respectively, at follow-up \[[@B24]\]. This study suggests that the treatment of candidemia with anidulafungin is as effective in Asian populations as Western populations. The crude mortality rate reported in this study (23%) was also similar to that observed in anidulafungin-treated candidemia patients in North America and Europe \[[@B12]\] and in line with data reported for other echinocandins \[[@B8]\]. These rates are substantially lower than the crude mortality (35% to 60%) associated with candidemia in Asian patients who had not received echinocandins \[[@B2],[@B4]\]. A more recent prospective multicenter Phase IIIb trial (ICE study) demonstrated that anidulafungin was effective and well tolerated with a good safety profile for the treatment of confirmed C/IC in critically ill patients from ≥ 1 of the following subpopulations: post-abdominal surgery, solid tumor, renal insufficiency, hepatic insufficiency, solid organ transplant, neutropenia (neutrophil count \< 500 cells/mm^3^), and age ≥ 65 years. The global success rate (both clinical and microbiological success) at EOT (69.5%) was similar to that achieved when anidulafungin is administered in a general population \[[@B13],[@B14]\].

The causative strains isolated in the trial included common *Candida* species found in Asia \[[@B2],[@B6]\]. *C. tropicalis* was the most commonly identified pathogen in this trial. This species is not common in Europe and North America, but data from our study in Asian patients show that it was successfully treated with anidulafungin. Successful responses against *C. albicans*, *C. parapsilosis*, and *C. glabrata* infections were also documented, in line with previous studies \[[@B2],[@B6]\].

As may be expected, the combined rates of microbiological eradication/presumed eradication were slightly higher than the clinical success rates. Global success was achieved in all patients who had baseline isolates resistant to anidulafungin or voriconazole, possibly due to catheter removal eliminating the source of infection. Therefore, the success of treatment of resistant isolates may not be counted as antifungal efficacy. There was no evidence of the development of resistance during active treatment, and there were no isolates that demonstrated an increase in MICs during the course of the study.

Patients with successful clinical responses at EOT had numerically lower mean β-D-glucan levels at baseline than those patients who later experienced clinical failure. This suggests the potential utility of this assay in determining the severity of infection and likely treatment prognosis, and further studies are warranted.

Although investigators had the option to step-down to oral voriconazole therapy after as few as 5 days of treatment with anidulafungin, the median duration of anidulafungin treatment was 11 days and only 14 patients were stepped-down to oral therapy. The duration of i.v. treatment was considerably longer than that reported in another short-course trial (6 days) \[[@B25]\] and was only 3 days shorter than reported in long-course therapy study (14 days) \[[@B12]\]. Possible reasons for this apparent reluctance to step-down to oral therapy at an early timepoint in this study may include the high percentage of non-*albicans* infections, the high proportion of critically ill post-abdominal surgery patients (who may have remained nil-by-mouth for a short period post-operation) and slower clinical response due to an immunocompromised state. It should be noted that during previous clinical studies of anidulafungin for C/IC, patients could be switched to oral fluconazole after completing the i.v. treatment period with anidulafungin \[[@B12]\]. However, due to the continuing increase in fluconazole-resistant strains \[[@B1],[@B6]\] and the high rate of fluconazole resistance in some Asian countries \[[@B6]\], voriconazole only was employed as oral step-down therapy in this study.

AEs were mostly mild or moderate, and consistent with the known favorable safety profile of anidulafungin, with no new safety concerns identified in this regional population \[[@B12],[@B26]\].

The slow enrollment rate in the study could have occurred due to several reasons. The use of fluconazole prophylaxis may have reduced the incidence of C/IC or led to less detection by blood culture, and many candidemic patients with APACHE II score between 20 and 25 were excluded as per the protocol. Other potential shortfalls of this study are the open-label design and the low number of enrolled patients with azole-resistant *Candida* strains (especially *C. krusei*).

Despite the small size, this study retains relevance to clinical practice. First, anidulafungin is easy to use in the clinic as it does not require dose adjustments for renal and hepatic impairment or for concomitant drug use \[[@B26]-[@B28]\]. This study included a number of patients who may have required dose adjustment in this study if a different echinocandin had been employed. Secondly, because the study focused on patients with APACHE II scores ≤ 20, the evaluation of clinical efficacy was less likely to be confounded by the severity of the patient's illness. Finally, anidulafungin demonstrated an efficacy and safety profile in Asian patients that was comparable to clinical trials in Western populations**.**

Conclusions
===========

Initial data are promising for a course of i.v. anidulafungin for the treatment of C/IC in Asian patients. Although the epidemiology of *Candida* infections was different in Asian patients, the efficacy of anidulafungin was in line with that previously observed in Western populations. Data from the trial showed that treatment of *C. tropicalis* was successful with i.v. anidulafungin. No new safety concerns were identified.
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=============

AE: Adverse event; APACHE II: Acute Physiology and Chronic Health Evaluation; BID: Twice-daily; CI: Confidence interval; C/IC: Candidemia/invasive candidiasis; EOIT: end of intravenous anidulafungin treatment; EOT: End of all treatment; ITT: Intent-to-treat; i.v.: Intravenous; MIC: Minimum inhibitory concentration; MITT: Modified intent-to-treat; SD: Standard deviation.

Competing interests
===================

PM has received speaker fees from Pfizer Inc. P-RH has received consultancy fees and honoraria from Pfizer Inc. DT has no relevant conflicts of interest to report. VMC has received honoraria and travel support from Pfizer Inc. VR is a former Pfizer employee and M-LO is a full-time employee of Pfizer Inc.

Authors' contributions
======================

VR and MLO conceived and designed the study. PM, PRH, DT, VMC, and VR performed the study. All authors reviewed and approved the final manuscript.

Pre-publication history
=======================

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2334/13/219/prepub>

Supplementary Material
======================

###### Additional file 1

List of investigators and corresponding ethics committees or institutional review boards.

###### 

Click here for file

Acknowledgments
===============

This study was sponsored by Pfizer Inc. Editorial support was provided by Dominik Wolf, of Parexel, and Anne Marie Reid, PhD, and Phil Matthews, PhD, at Complete Medical Communications, and was funded by Pfizer Inc. The authors would like to thank Dr Haran Schlamm and Dr Stephen Lin of Pfizer for their support, advice, critical review, and guidance throughout the manuscript development, and Dr Sharon Pan of Pfizer for statistical analysis.

The following laboratories completed laboratory assessments (i.e. chemistry, cultures, and β-D-glucan) during the study: **Thailand:** Microbiology Laboratory and Department of Laboratory Medicine, King Chulalongkorn Memorial Hospital, Bangkok; Central Diagnostics Laboratory, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai; Division of Clinical Laboratory, Srinagarind Hospital, Khon Kaen. **Taiwan:** Department of Laboratory Medicine, National Taiwan University Hospital, Taipei; Department of Laboratory Medicine, China Medical University Hospital, Taichung City; Department of Pathology, National Cheng Kung University Hospital, Tainan City; Department of Pathology, Far Eastern Memorial Hospital, Taipei; Department of Infection, National Taiwan University Hospital, Taipei. **Philippines:** Research Institute for Tropical Medicine, Department of Health Compound, Muntinlupa City; Makati Medical Center, Makati City. **India:** Metropolis Health Services Ltd, Mumbai; SRL Ranbaxy Limited, Mumbai, India.
